Neil JC - Search Results

1

Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.

Hay J, Gilroy K, Huser C, Kilbey A, Mcdonald A, MacCallum A, Holroyd A, Cameron E, Neil JC. Hay J, et al. Among authors: neil jc. J Cell Biochem. 2019 Oct;120(10):18332-18345. doi: 10.1002/jcb.29143. Epub 2019 Jun 30. J Cell Biochem. 2019. PMID: 31257681 Free PMC article.

2

Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.

Borland G, Kilbey A, Hay J, Gilroy K, Terry A, Mackay N, Bell M, McDonald A, Mills K, Cameron E, Neil JC. Borland G, et al. Among authors: neil jc. Oncotarget. 2016 Apr 26;7(17):22973-87. doi: 10.18632/oncotarget.8554. Oncotarget. 2016. PMID: 27056890 Free PMC article.

3

RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins.

Anderson G, Mackay N, Gilroy K, Hay J, Borland G, McDonald A, Bell M, Hassanudin SA, Cameron E, Neil JC, Kilbey A. Anderson G, et al. Among authors: neil jc. J Cell Biochem. 2018 Mar;119(3):2750-2762. doi: 10.1002/jcb.26443. Epub 2017 Nov 20. J Cell Biochem. 2018. PMID: 29052866 Free PMC article.

4

Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis.

Kilbey A, Terry A, Wotton S, Borland G, Zhang Q, Mackay N, McDonald A, Bell M, Wakelam MJ, Cameron ER, Neil JC. Kilbey A, et al. Among authors: neil jc. J Cell Biochem. 2017 Jun;118(6):1432-1441. doi: 10.1002/jcb.25802. Epub 2017 Jan 10. J Cell Biochem. 2017. PMID: 27869314 Free PMC article.

5

Runx2 in normal tissues and cancer cells: A developing story.

Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER. Blyth K, et al. Blood Cells Mol Dis. 2010 Aug 15;45(2):117-23. doi: 10.1016/j.bcmd.2010.05.007. Epub 2010 Jun 26. Blood Cells Mol Dis. 2010. PMID: 20580290

6

Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model.

Loyola L, Achuthan V, Gilroy K, Borland G, Kilbey A, Mackay N, Bell M, Hay J, Aiyer S, Fingerman D, Villanueva RA, Cameron E, Kozak CA, Engelman AN, Neil J, Roth MJ. Loyola L, et al. PLoS Pathog. 2019 Dec 9;15(12):e1008154. doi: 10.1371/journal.ppat.1008154. eCollection 2019 Dec. PLoS Pathog. 2019. PMID: 31815961 Free PMC article.

7

Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection.

Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER. Vaillant F, et al. Among authors: neil jc. J Immunol. 2002 Sep 15;169(6):2866-74. doi: 10.4049/jimmunol.169.6.2866. J Immunol. 2002. PMID: 12218099

8

Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.

Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, Neil JC, Cameron ER. Wotton S, et al. Among authors: neil jc. Cancer Res. 2002 Dec 15;62(24):7181-5. Cancer Res. 2002. PMID: 12499254

9

The Runx genes as dominant oncogenes.

Cameron ER, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S, Neil JC. Cameron ER, et al. Among authors: neil jc. Blood Cells Mol Dis. 2003 Mar-Apr;30(2):194-200. doi: 10.1016/s1079-9796(03)00031-7. Blood Cells Mol Dis. 2003. PMID: 12732183 Review.

10

RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53.

Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F, Friedman AD, Baxter EW, Neil JC, Cameron ER. Wotton SF, et al. Among authors: neil jc. Oncogene. 2004 Jul 15;23(32):5476-86. doi: 10.1038/sj.onc.1207729. Oncogene. 2004. PMID: 15133495

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page